Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?

Best Practice and Research in Clinical Haematology

Volumn 20, Issue 4, 2007, Pages 783-795

  Bensinger, William I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

allogeneic stem cell transplantation; multiple myeloma

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HOLMIUM; HOLMIUM 166; LENALIDOMIDE; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; NURSE CLINICIANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 36749018521     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.09.007     Document Type: Review

References (54)

1. Kumar S., and Anderson K.C. Drug insight: thalidomide as a treatment for multiple myeloma. (Review). Nature Clinical Practice Oncology 2 (2005) 262-270
2. Anderson K.C., Shaughnessy Jr. J.D., Barlogie B., et al. Multiple myeloma. In: Broudy V.C., Abkowitz J.L., and Vose J.M. (Eds). Hematology 2002: American Society of Hematology Education Program Book (2002), American Society of Hemtology, Washington, DC 214-240
3. Tricot G., Vesole D.H., Jagannath S., et al. Graft-versus-myeloma effect: Proof of principle. Blood 87 (1996) 1196-1198
4. Verdonck L.F., Lokhorst H.M., Dekker A.W., et al. Graft-versus-myeloma effect in two cases. Lancet 347 (1996) 800-801
5. Aschan J., Lonnqvist B., Ringden O., et al. Graft-versus-myeloma effect. (Letter). Lancet 348 (1996) 346
6. Le Blanc R., Montminy-Métivier S., Bélanger R., et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplantation 28 (2001) 841-848
7. Libura J., Hoffmann T., Passweg J., et al. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplantation 24 (1999) 925-927
8. Bertz H., Burger J.A., Kunzmann R., et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeniec bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11 (1997) 281-283
9. Salama M., Nevill T., Marcellus D., et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplantation 26 (2000) 1179-1184
10. Collins Jr. R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology 15 (1997) 433-444
11. Alyea E, Ritz J., Induction of graft-versus-myeloma by donor lymphocyte infusions following allogeneic bone marrow transplant. In Anderson KC (ed) VI International Workshop on Multiple Myeloma 1997.
12. Mehta J., and Singhal S. Graft-versus-myeloma. (Review). Bone Marrow Transplantation 22 (1998) 835-843
13. Kroger N., Perez-Simon J.A., Klingemann H., et al. Relapse to prior autograft and chronic graft-vs-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of Blood and Marrow Transplantation 10 (2004) 698-708
14. Einsele H., Schäfer H.J., Bader P., et al. Allografts after reduced intensity conditioning can induce long-term remission in patients with chemosensitive relapsed multiple myeloma (MM). Blood 100 Part 1 (2002) 635a #2499
15. Cwynarski K., Dazzi F., Cross N.C.P., et al. Response to donor lymphocyte infusions (DLI) of patients with CML in relapse after allografting: a long-term follow-up study using RT-PCR. Blood 94 supplement 1 (1999) 669a #2968
16. Dazzi F., Szydlo R.M., Cross N.C., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96 (2000) 2712-2716
17. Helg C., Starobinski M., Jeannet M., et al. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. (Review). Leukemia & Lymphoma 29 (1998) 301-313
18. Storb R., Yu C., Sandmaier B., et al. Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplantation Proceedings 31 (1999) 677-678
19. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
20. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
21. Lee C.-K., Badros A., Barlogie B., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Experimental Hematology 31 (2003) 73-80
22. Hoepfner S., Probst S.M., Breitkreutz I., et al. Non-myeloablative allogeneic transplantation as part of salvage therapy for relapse of multiple myeloma after autologous transplantation. Blood 100 Part 1 (2002) 859a #3387
23. Giralt S., Aleman A., Anagnostopoulos A., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplantation 30 (2002) 367-373
24. Einsele H., Schafer H.J., Hebart H., et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. British Journal of Haematology 121 (2003) 411-418
25. Qazilbash M.H., Saliba R., de Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 106 (2006) 1084-1089
26. Elice F., Raimondi R., Tosetto A., et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. American Journal of Hematology 81 (2006) 426-431
27. Kroger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
28. Kroger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100 (2002) 3919-3924
29. Galimberti S., Benedetti E., Morabito F., et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leukemia Research 29 (2005) 961-966
30. Peggs K.S., Mackinnon S., Williams C.D., et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biology of Blood and Marrow Transplantation 9 (2003) 257-265
31. Mohty M., Boiron J.M., Damaj G., et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation 34 (2004) 77-84
32. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
33. Crawley C., Iacobelli S., Bjorkstrand B., et al. Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning. Blood 109 (2007) 3588-3594
34. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
35. Kroger N., Schilling G., Einsele H., et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103 (2004) 4056-4061
36. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly-diagnosed myeloma. The New England Journal of Medicine 356 (2007) 1110-1120
37. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology 24 (2006) 929-936
38. Majolino I., Corradini P., Scimè R., et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplantation 22 (1998) 449-455
39. 166HO-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood 102 (2003) 2684-2691
40. Dispenzieri A., Wiseman G.A., Lacy M.Q., et al. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia 19 (2005) 118-125
41. Kennedy G.A., Durrant S., Butler J., et al. Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen. Leukemia 19 (2005) 879-880
42. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. The New England Journal of Medicine 344 (2001) 175-181
43. Macfarlane D.J., Durrant S., Bartlett M.L., et al. 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies. Nuclear Medicine Communications 23 (2002) 1099-1106
44. 166Ho-DOTMP plus melphalan with or without total body irradiation (TBI) and autologous hematopoietic stem cell transplant (AHSCT). Blood 100 Part 1 (2002) 179a #670
45. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
46. Champlin R., Giralt S., Gajewski J., et al. CD8 depleted donor lymphocytes for CML relapsing post BMT. International Society for Experimental Hematology 23 (1995) 939
47. Kroger N., Shaw B., Iacobelli S., et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. British Journal of Haematology 129 (2005) 631-643
48. Bensinger W., Jagannath S., Becker P.S., et al. A phase 1 dose escalation study of a fully human antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. Blood 108 Part 1 (2006) 1021a #3575
49. Hsi E.D., Steinle R., Balasa B., et al. CS1: a potential new therapeutic target for the treatment of multiple myeloma. Blood 108 Part 1 (2006) 986a #3457
50. Hussein M.A., Berenson J.R., Niesvizky R., et al. A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood 106 Part 1 (2005) 723a #2572
51. Gerull S., Goerner M., Benner A., et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplantation 36 (2005) 963-969
52. Ma S.Y., Lie A.K., Au W.Y., et al. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma. Hong Kong Medical Journal 10 (2004) 77-83
53. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biology of Blood and Marrow Transplantation 12 (2006) 375-396
54. Sorasio R., Giaccone L., Patriarca F., et al. Unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with high risk multiple myeloma. Blood 108 Part 1 (2006) 901a #3158